论文部分内容阅读
目的观察优泌乐50和诺和锐30治疗初诊断2型糖尿病疗效。方法选择56例初诊断2型糖尿病患者,随机分为两组,进行优泌乐50和诺和锐30的交叉对照试验。观察治疗后空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、胰岛素(RI)用量、体重指数(BMI)、低血糖的发生情况等各项指标的变化,从而比较治疗效果。结果两组空腹血糖控制水平相似,而优泌乐50组餐后血糖控制优于诺和锐30组,且HbA1c水平更低,RI用量也少,差异有统计学意义(P<0.05)。两组低血糖发生率差异无统计学意义(P>0.05),但优泌乐50白天低血糖发生较多(P<0.05),诺和锐30夜间低血糖发生较多(P<0.05)。结论优泌乐50和诺和锐30治疗2型糖尿病均疗效肯定,但优泌乐50对餐后血糖的控制存在优势,胰岛素用量更少,且夜间低血糖事件较少。
Objective To observe the curative effect of Urethane 50 and Novo-Rui 30 on newly diagnosed type 2 diabetes. Methods Fifty-six patients with newly diagnosed type 2 diabetes mellitus were randomly divided into two groups, and the cross-over control trial was conducted with Eruxylol 50 and Novo-Rui-30. The changes of fasting blood glucose (FPG), postprandial 2h blood glucose (2hPG), HbA1c, insulin (RI), body mass index (BMI) and the incidence of hypoglycemia were observed. treatment effect. Results The fasting blood glucose control was similar in both groups. The postprandial blood glucose control in 50 Ureteral Striatum groups was better than that in Novo Rui 30 group, and the HbA1c level was lower and the RI dosage was lower. The difference was statistically significant (P <0.05). There was no significant difference in the incidence of hypoglycaemia between the two groups (P> 0.05). However, there were more hypoglycemic episodes of Uehara 50 in the daytime (P <0.05). Conclusion Ursolic acid 50 and Novo-Rui 30 are effective in treating type 2 diabetes. However, Ueger 50 has some advantages in controlling postprandial blood glucose, with less insulin dosage and less nighttime hypoglycemic events.